

VERTEX PHARMACEUTICALS INC / MA

Form 3

August 22, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2015

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Thomas Connolly
 (Last) (First) (Middle)

2. Date of Event Requiring Statement

08/13/2013
 (Month/Day/Year)

3. Issuer Name and Ticker or Trading Symbol

VERTEX PHARMACEUTICALS INC / MA [VRTX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 SVP, Human Resources

C/O VERTEX
 PHARMACEUTICALS
 INCORPORATED, 130
 WAVERLY ST.

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

5,002 ⁽¹⁾

D

À

Common Stock

150

I

401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	Â (2)	09/03/2022	Common Stock	12,188	\$ 53.74	D	Â
Employee Stock Option (right to buy)	Â (3)	02/04/2023	Common Stock	13,125	\$ 45.11	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Connolly Thomas C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE, MA 02139	Â	Â	Â SVP, Human Resources	Â

Signatures

Kenneth L. Horton, 08/22/2013
Attorney-In-Fact

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes (a) 3,000 shares of common stock vesting in four equal installments on 9/30/2013, 9/30/2014, 9/30/2015 and 9/30/2016; and (b) 2,000 shares of common stock vesting on 2/5/2017, subject to acceleration upon achievement of company performance goals.
- (2) This stock option, which on the grant date was for 15,000 shares, vests in 16 quarterly installments from 9/4/2012.
- (3) This stock option, which on the grant date was for 15,000 shares, vests in 16 quarterly installments from 2/5/2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.